Cite
HARVARD Citation
Gschwind, L. et al. (2013). Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug–drug interactions during acenocoumarol treatment. Pharmacogenomics. pp. 745-753. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gschwind, L. et al. (2013). Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug–drug interactions during acenocoumarol treatment. Pharmacogenomics. pp. 745-753. [Online].